Beprogel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beprogel

Property Description
Active Ingredient Betamethasone Dipropionate
Form Topical Solution, Gel (External Use)
Pharmacological Class Corticosteroid (Glucocorticoid)
General Purpose Management of inflammatory skin symptoms
Origin Synthetic adrenocorticosteroid

What Type of Medicine is Beprogel and What is its Composition?

Beprogel is a prescription-only (Rx only) topical medicine identified by its active ingredient, Betamethasone Dipropionate, and is classified as a potent topical corticosteroid. This medication belongs to the glucocorticoid subclass of drugs, which are synthetic analogs designed to mimic the action of naturally produced steroid hormones. It is clinically recognized for its potent classification, distinguishing it from lower-strength, over-the-counter hydrocortisone preparations.

This formulation is fundamentally a single-agent product, relying entirely on the therapeutic action of Betamethasone Dipropionate, a fluorinated, synthetic adrenocorticosteroid. The compound's chemical structure as the 17,21-dipropionate ester of betamethasone is specifically engineered to provide high localized corticosteroid activity, which is a key design aspect of its potent composition.

Dosage Forms and General Therapeutic Purpose

Beprogel is formulated for topical dermatologic use and is typically available in various dosage forms, notably as a non-greasy Topical Solution or a Gel, which utilize vehicles suitable for efficient external application, particularly on hairy areas like the scalp. The core purpose of the medicine is to serve as a potent anti-inflammatory agent for the management of skin conditions generally responsive to this class of medication.

Topical corticosteroids like Betamethasone Dipropionate possess strong anti-inflammatory, anti-pruritic (anti-itching), and vasoconstrictive actions. This means the medication works to suppress key inflammatory symptoms, including excessive redness, associated swelling, and intense itchiness, providing relief in typical scenarios of severe dermatological inflammation.

Regulatory References

  1. Steroids (Corticosteroids/Glucocorticoids)
  2. Betamethasone Dipropionate Drug Label/Monograph (DailyMed)

What side effects are possible with Beprogel?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety statements for Beprogel as documented in official government regulatory information.

Adverse Reaction Frequency and Types

Side effects are categorized by how often they occur, ranging from Very Common (ge 1/10) to Not Known (frequency cannot be estimated from available data). Most common effects are local and generally expected.

Classification Examples of Documented Reactions
Common Application site reactions (e.g., pain, burning, irritation, discomfort), pruritus (itching), dry skin, erythema.
Serious Adverse Reactions Systemic Hypersensitivity Reactions (e.g., angioedema), severe secondary infection, and effects related to systemic absorption.

Adverse reactions are also classified by the System-Organ Classes (SOC) they affect, including Skin and subcutaneous tissue disorders, General disorders and administration site conditions, Immune system disorders, and Endocrine disorders.

Safety Constraints and Considerations

Official labeling defines specific safety limitations and considerations:

  • Duration and Exposure: The risk of systemic adverse effects, such as HPA-axis suppression (an endocrine effect), increases with prolonged use or application over large surface areas. Local effects are often more common during the first week of treatment.
  • Contraindications: Use is contraindicated in patients with known hypersensitivity to the active substance or any excipient.
  • Vulnerable Populations: Specific precautions or use limitations are documented for populations such as pediatrics (due to increased risk of systemic absorption) and women who are pregnant or lactating, where risk-benefit assessment is mandatory.
  • Monitoring: The potential for HPA-axis suppression requires periodic assessment using appropriate laboratory tests, as defined in regulatory documents.

Overdose and Emergency Response

️ Overdose and when to seek help

The official overdose profile for Beprogel (Topical Betamethasone Dipropionate) is defined by systemic absorption resulting from excessive or prolonged use, rather than acute ingestion.

Overdose Scope

Category Official Regulatory Statements
Documented overdose presentations: Manifestations of Cushing's syndrome and the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Systemic effects include hyperglycemia and glucosuria.
Physiological systems affected: Primarily the Endocrine System and Metabolic System.
Dose-related or exposure-related factors: Risk increases with prolonged or excessive use, application over large surface areas, or use with occlusive dressings.
Population-specific overdose notes: Pediatric patients are at greater risk of systemic toxicity. Specific severe outcomes include linear growth retardation and intracranial hypertension.

Emergency Actions and Monitoring

Category Official Regulatory Statements
When immediate medical help is required: When manifestations of Cushing's syndrome or HPA axis suppression are suspected or confirmed. Urgent attention is also required if severe steroid withdrawal symptoms occur.
Mandated procedures: Official guidance requires periodic evaluation for HPA axis suppression using laboratory tests, such as the ACTH stimulation test.
Management Measures: If suppression is documented, official action requires the drug to be gradually withdrawn or a less potent corticosteroid substituted. No specific antidote is known for the systemic toxicity.

This profile dictates that help-seeking conditions are tied to monitoring for specific physiological imbalances, with controlled withdrawal being the mandated management strategy for confirmed systemic effects.

Therapeutic Uses of Beprogel

Quick Facts

Therapeutic Domain Main Uses
Skin Conditions Used to address inflammatory and itchy skin manifestations associated with certain dermatoses.
Specific Diagnoses May be utilized for managing conditions like psoriasis and eczema.

What Beprogel treats: main uses and benefits

Beprogel is a medication prescribed to address the visible signs and physical discomfort associated with various skin conditions. Its main purpose is to provide relief for inflammatory and pruritic (itchy) manifestations of dermatoses that are responsive to corticosteroid therapy.

The therapeutic action of this medication is associated with addressing discomfort such as redness, swelling, and itching that may be present in the affected area. It is primarily utilized in a managed treatment plan for conditions like psoriasis and eczema.

Beprogel may be considered an option for patients experiencing these challenging skin issues when determined appropriate by a healthcare professional. The treatment helps to manage the visible symptoms of these skin conditions, promoting comfort and supporting the skin’s appearance.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Beprogel

This eligibility profile is based on official government regulatory documents for Betamethasone, the active corticosteroid ingredient in Beprogel.

Contraindicated Populations

  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to betamethasone or any other ingredient in the product must not use this medicine.
  • Active Skin Conditions: Use is contraindicated on certain localized skin issues, including ulcers, acne lesions, and skin infections caused by viruses (such as herpes), fungi, or bacteria.

Populations Requiring Restricted Use

  • Pediatric Patients: Use in children, particularly those under 13 years for some formulations, is generally not recommended due to an increased risk of systemic absorption and side effects.
  • Pregnancy and Lactation: Use during pregnancy is conditional; it is considered only if the potential benefit justifies the risk to the fetus (Category C). Smallest effective amounts should be used. For breastfeeding, application must be avoided on the nipple and surrounding area.
  • Comorbidities: Use requires caution in individuals with pre-existing systemic conditions that may be affected by corticosteroid absorption, such as liver or kidney impairment, Cushing's syndrome, or diabetes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official regulatory information regarding potential interactions involving Beprogel, a topical corticosteroid-containing medicine. The primary concern is related to systemic absorption of the active ingredient, which can be enhanced by specific factors.

Interaction Focus: Additive Systemic Exposure

Interacting Product Category Regulatory Concern
Other Corticosteroids (Topical or Systemic) Concomitant use with other corticosteroid-containing products may increase the overall systemic exposure and risk of conditions associated with elevated corticosteroids, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's syndrome.

Population-Specific Interaction Notes

Official regulatory documents note that the risk of systemic effects, which are linked to the potential for interaction, is elevated in certain patient groups:

  • Pediatric Patients: Children are at a greater risk of systemic toxicity and HPA axis suppression compared to adults due to a higher skin surface area-to-body mass ratio, leading to enhanced systemic absorption.
  • Patients with Liver Impairment: Individuals with impaired liver function may experience enhanced corticosteroid effects due to potentially decreased metabolism of the active ingredient.

Interaction Summary

The interaction structure is defined by the necessary regulatory precaution against the additive effects of combining this topical medicine with any other systemic or topical corticosteroids. This constraint is based on the potential for clinically relevant systemic absorption of the active ingredient, necessitating professional caution when considering co-administration of products containing the same drug class.

Mechanism of Action

How Beprogel Works

Beprogel exerts effects through engagement with multiple distinct mechanisms that alter activity within specific physiological pathways at the cellular and molecular level. It operates within systems where pathway activity is subject to modification.

Receptor-Mediated Signaling Modulation

Beprogel acts within domains involving receptor-mediated signaling by binding to specific cytosolic receptors. This action modifies early molecular steps, initiating or suppressing the signaling sequences that lead to downstream transcriptional changes. The resulting physiological effect includes the modulation of cellular response magnitude by altering the sensitivity of targeted cells.

Key Pathway Cascade Suppression

The drug is relevant in cascades where multiple layers of pathway activation occur, engaging mechanisms that influence feedback regulation within inflammatory pathways. Beprogel modifies the activity of key enzymes or mediators, resulting in reduced levels of specific mediator activity. This results in changes in pathway signaling dynamics following the inhibition of specific activation signals.

Dosage and Administration Information

Administration of Beprogel

Beprogel is a topical medication intended for application directly to the affected areas of the skin. It is typically formulated as a gel to facilitate absorption and ease of spread over the cutaneous surface.

Application Technique

The gel should be applied in a thin layer, ensuring even coverage of the specific site being treated. It is generally advised to clean and dry the skin area before application. Users should wash their hands thoroughly before and after applying the gel, unless the hands themselves are the area requiring treatment.

Usage Considerations

  • Targeted Areas: The application should be confined to the skin surfaces identified for treatment. Avoid contact with the eyes, mouth, or internal mucosal surfaces.
  • Absorption: To allow for proper absorption, the treated area should not be covered with tight bandages or occlusive dressings unless specifically indicated for the condition being treated.
  • Consistency: Maintaining a regular schedule for application helps ensure the medication remains effective throughout the treatment period.

Recent Clinical Evidence

Beprogel: Recent Clinical Evidence


Evidence for Use in Plaque Psoriasis

Research into Betamethasone Dipropionate (Beprogel) for plaque psoriasis primarily relies on short-to-medium-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies evaluated the medicine against non-medicated vehicles and other topical treatments, examining patient groups including Adults and Adolescents (age 12 and older). The studies monitored outcomes related to physical discomfort using standardized tools like the Investigator's Global Assessment (IGA) and the Psoriasis Area and Severity Index (PASI), as well as patient-reported outcomes (PROs).

Findings describe patterns related to measured changes in symptoms such as scaling, redness, and itching during the observation periods. Studies report how symptoms evolved in the observed populations, and research provides insight into the recorded status of symptoms as monitored by clinicians and patients.


Evidence for Other Corticosteroid-Responsive Dermatoses

The medicine was also studied for conditions characterized by fluctuating manifestations, such as eczema (Atopic Dermatitis), which research explores for this type of medicine. This evidence includes various RCTs integrated into the broader evidence landscape for the topical corticosteroid class. Studies examined outcomes linked to inflammatory states, focusing on assessing signs like the extent of redness, swelling, and induration over periods typically lasting 3 to 6 weeks. Findings generally reflect group patterns, and research does not determine whether an individual will respond similarly.


Duration of Evidence and Research Gaps

Most core efficacy trials spanned 2 weeks up to 8 weeks, focusing on short-term symptom patterns. Long-term effects are not fully established by the core research, and limited information exists on the durability of findings or the need for maintenance treatment. Data for certain groups, such as younger children, remain insufficient.

A key limitation is that documentation notes that findings were dependent on the specific formulation (or vehicle) used, meaning that data from studies using a cream or ointment may differ from the patterns observed with the topical solution or gel formulation. Furthermore, the overall evidence quality varies across studies.

Key Studies & References

  1. Label: BETAMETHASONE DIPROPIONATE cream (Augmented) - DailyMed (NIH)
  2. Label: BETAMETHASONE DIPROPIONATE gel (Augmented) - DailyMed (NIH)
  3. Label: BETAMETHASONE DIPROPIONATE spray - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Beprogel (FAQ)


Q: How quickly should I expect Beprogel to start working?

Official patient information indicates that signs of improvement in symptoms may begin to appear after a few days of using the medicine. However, achieving the intended therapeutic effect may require using the medicine for the full treatment time described in the guidelines.


Q: Is it common to feel a slight stinging or burning when first applying Beprogel?

Yes, regulatory documents list a temporary sensation of burning, stinging, itching, or irritation at the application site as a common adverse reaction. These sensations are often reported upon initial application to the skin.


Q: What kind of research has been done on Beprogel for long-term use?

Most core efficacy trials focused on short-term symptom patterns, spanning periods up to eight weeks. Official documents state that long-term effects and the durability of findings are not fully established by the core research evidence available.


Q: What is the difference between Beprogel and a placebo in clinical trials?

Clinical research for Beprogel evaluated the medicine against non-medicated vehicles, often called a placebo. Studies describe measured changes in symptoms such as scaling, redness, and itching, which reflects the therapeutic benefit observed when compared to using the vehicle alone.


Q: What is the main mechanism described for how Beprogel achieves its effects?

Beprogel is officially described as working as an anti-inflammatory, anti-pruritic (anti-itching), and vasoconstrictive agent. Its effects are achieved through the modulation of cellular signaling and the suppression of key activity within the body's inflammatory pathways.


Q: Can Beprogel be used on broken skin or open wounds?

Topical corticosteroids are not generally indicated for use on certain localized skin issues, including ulcers. Furthermore, the extent of medicine absorption may be increased when the skin barrier is not intact, which may increase the risk of systemic effects.


Q: How long after starting Beprogel is a follow-up visit usually recommended by healthcare providers?

Regulatory documents require that patients using topical corticosteroids have their progress checked at regular visits by a healthcare professional to monitor for any unwanted effects. Monitoring, often including periodic laboratory testing, may be required to check for systemic effects, such as HPA axis suppression.


Q: Does Beprogel absorb into the body beyond the skin?

Yes, official documents indicate that topical corticosteroids can be absorbed through normal, intact skin in amounts sufficient to produce effects beyond the treated area. The amount absorbed is affected by factors such as the integrity of the skin barrier, the duration of use, and whether occlusive (airtight) dressings are applied.


Q: Is Beprogel available over the counter, or is it prescription-only?

Beprogel is classified as a potent topical corticosteroid and is designated as prescription-only (Rx only) medicine. It is not available for purchase over the counter.


Q: Does Beprogel have any ingredients that are known allergens?

Use of the medicine is contraindicated in individuals with a known hypersensitivity or allergy to the active substance or any other component (excipient) in the preparation. Official warnings also note that allergic contact dermatitis may occur with the use of topical corticosteroids.


Q: Can Beprogel be used at the same time as my regular moisturizer?

Patient instructions found in official documents advise against using cosmetics or other skin care products, which may include moisturizers, on the treated areas while using this medication.


Q: Are there any specific foods or drinks that interact with Beprogel?

The official drug labeling does not list specific foods or drinks that interact with Beprogel. However, general patient guidance recommends discussing the use of any medicine with food, alcohol, or tobacco with a healthcare professional.


Q: Is there a generic version of Beprogel available?

Yes, official dispensing information confirms that medicines containing the same active ingredient, Betamethasone Dipropionate, are available in generic versions.


Q: Why do official sources mention 'discontinue use if irritation occurs'?

Official labeling states that if irritation, sensitivity, or infection develops, the topical corticosteroid should be discontinued. This is required so that appropriate therapy can be instituted to address the new or worsening skin condition.


Q: Are there any common reasons why Beprogel might not work for someone?

A common reason for lack of favorable response, according to official warnings, may be related to the presence of an underlying dermatological infection. Regulatory instructions suggest discontinuing the medicine until an appropriate antifungal or antibacterial agent has adequately controlled the infection.


Q: Is it true that Beprogel can sometimes cause changes in skin color?

Adverse reaction reports for topical corticosteroids include potential changes in skin color in the treated areas. This is specifically documented as hypopigmentation (lightening of the skin).


Q: Is Beprogel linked to any specific long-term health risks?

Prolonged use of this class of medicine, especially over large surface areas, increases the risk of systemic side effects. These risks may include the suppression of the HPA axis (an endocrine effect), Cushing's syndrome, and vision problems such as cataracts and glaucoma.


Q: If I miss a planned use of Beprogel, should I just wait for the next scheduled time?

Official patient instructions advise that if a dose is missed, it should be applied as soon as remembered. However, if it is near the time of the next scheduled use, the missed application is typically skipped in favor of the next regular time. Official instructions advise against doubling the application.


Q: Are there specific times of day that Beprogel is usually recommended for use?

The required dosing frequency is typically once or twice daily. When a twice-daily schedule is described, official instructions for some forms suggest application in the morning and at night.


Q: What is the shelf life of Beprogel once the container is opened?

Official documents specify that the in-use stability for the topical spray formulation is 4 weeks after opening, after which it must be discarded. Patients should check the product-specific package information for the stability of other formulations like the gel or solution.


Q: Are there any specific activities or environments (like swimming) to avoid while using Beprogel?

Official patient instructions advise protecting the treated skin area from water, clothing, or anything that causes rubbing until the medicine has dried. Additionally, avoiding excessive exposure to natural or artificial sunlight may be recommended with some specific formulations.


Q: Why is Beprogel not recommended for use on large areas of the body?

The risk of systemic side effects, such as the suppression of the HPA-axis (Hypothalamic-Pituitary-Adrenal axis, an endocrine effect), increases when the medicine is applied over large surface areas of the body.


Q: Is Beprogel known to cause headaches or general body side effects?

Systemic side effects are possible because of absorption into the body, although they are generally rare for topical use. Headaches have been reported, and other systemic effects may include blurred vision, dizziness, or changes in thirst or urination.


Q: What is the difference between Beprogel and a similar topical cream I used before?

Beprogel contains the potent corticosteroid Betamethasone Dipropionate. This medicine is stronger than many other topical preparations, including over-the-counter hydrocortisone 1%. The specific strength and formula are determined by a healthcare provider for specific conditions.


Q: How is Beprogel different from other topical products in its class?

The active ingredient in Beprogel is generally classified as a highly potent topical corticosteroid. Specific formulations are engineered to absorb differently than other medicines in the same drug class, which leads to differences in overall strength and effect profile.


Q: Can Beprogel be used by someone who is taking multiple other medications?

The primary concern for interaction in official documents is the combined use with other topical or systemic corticosteroids, which increases the risk of systemic side effects. No other comprehensive interactions are typically described for this topical medicine.


How should Beprogel be stored and disposed of?

How to Store and Dispose of Beprogel?

This section explains the official regulatory requirements for storing, protecting, handling, and disposing of Beprogel (betamethasone dipropionate).

Labeled Storage Requirements

  • Temperature: Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F).
  • Protection: The medicine must be protected from both heat and direct light. It should be kept in a tightly closed container and must not be frozen.
  • Child Safety: It is strictly required to keep this medicine out of the reach of children and store it securely.

Stability and Disposal Instructions

  • In-Use Stability: The topical spray formulation must be discarded after 4 weeks of use (4 weeks after opening).
  • Disposal: Any outdated or no longer needed medicine must be thrown away. Consult a healthcare professional or follow local waste disposal regulations for proper and safe discard procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beprogel found in:

A-Z Index: